EyePoint Pharmaceuticals, Inc. EYPT · Stock Open EyePoint Pharmaceuticals, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
EyePoint Pharmaceuticals, Inc. Analysis (EYPT)
Is EyePoint Pharmaceuticals, Inc. a good investment? EyePoint Pharmaceuticals, Inc. (EYPT) is currently trading at 0.4045 USD. Market analysts have a consensus price target of 8.44 USD. This suggests a potential upside from current levels.
Earnings Schedule: EyePoint Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -2.20.
Investor FAQ
Does EyePoint Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is EyePoint Pharmaceuticals, Inc.?
EyePoint Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -3.75.
Company Profile
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| June 11, 2008 | 1:4 |
| Dec. 9, 2020 | 1:10 |
Community Discussion